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Modulation of abnormal amyloid β (Aβ) aggregation is considered to be a potential therapeutic target for
Alzheimer’s disease (AD). Recent in vitro and in vivo experiments suggest that inhibition of Aβ ag-
gregation by curcumin would exert favorable effects for preventing or treating AD. We have previously
synthesized a series of novel curcumin derivatives. In this study, we investigated the effects of our
curcumin derivatives on Aβ aggregation and the cell toxicities of Aβ aggregates. According to sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) proﬁles, 14 of 41 compounds showed a
signiﬁcant increase in the densities of the bands of Aβ (1–42) by incubation during the aggregation
process relative to those of Aβ (1–42) prepared in the presence of the vehicle control. Of the 14 com-
pounds, four compounds additionally reduced cell toxicity of the Aβ aggregates by incubation during the
aggregation process. A signiﬁcant positive correlation was observed between the cell viability and
densities of the bands at ranges of 15–20, 20–37, 37–75, and 75–200 kDa in SDS-PAGE. On the basis of
these results, we propose four curcumin derivatives with potential for preventing AD. These curcumin
derivatives exhibited high inhibitory effects on Aβ aggregation and induced the formation of lower
molecular size Aβ species that have weaker cell toxicity. These compounds may exert therapeutic effects
on AD in future in vivo studies.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD) is characterized by a progression from
episodic memory difﬁculties to a slow global decline in cognitive
function [1,2]. Recent studies on the progression of AD strongly
support the amyloid cascade hypothesis that a pathological change
in amyloid β (Aβ) in the brain is an initiating event in AD [3,4]. Aβ
is normally and ubiquitously expressed throughout life as peptides
of mainly 40 and 42 residues. By unknown mechanisms, mono-
meric Aβ polymerizes, forms long insoluble ﬁbrillar aggregates,
and accumulates in extracellular deposits known as senile plaques.
Such abnormal aggregates of Aβ are believed to induce hyper-
phosphorylation of tau, tangle formation, and neuronal loss, which
eventually results in cognitive impairment. Accordingly, modula-
tion of abnormal Aβ aggregation is considered to be a potential
therapeutic target for AD.
Curcumin, a polyphenol, is a low-molecular weight yellow-B.V. This is an open access article u
Tooyama).orange pigment derived from the well-known curry spice tur-
meric, obtained from the rhizome of Curcuma longa. Curcumin
may have numerous biochemical and molecular targets, including
transcription factors, inﬂammatory cytokines, enzymes, kinases,
growth factors, receptors, adhesion molecules, and anti-apoptosis
proteins, as described in the review by Goel et al. [5]. In addition,
recent in vitro and in vivo experiments suggest that the inhibitory
effect of curcumin on Aβ aggregation would be favorable for pre-
venting or treating AD [6–12].
We recently reported a novel curcumin derivative, 1,7-bis (4′-
hydroxy-3′-triﬂuoromethoxyphenyl)-4-methoxycarbonylethyl-
1,6-heptadiene-3,5-dione (FMeC1), as a ﬂuorine-19 magnetic re-
sonance imaging (MRI) probe to detect amyloid deposition in the
brain [13–15]. FMeC1 penetrated the blood–brain barrier and
bound to amyloid plaques in a transgenic mouse model of AD after
injection via the tail vein. Because FMeC1 has six atoms of ﬂuorine
in its structure, FMeC1 accumulation can be detected in the mouse
brain using ﬂuorine-19 MRI. Treatment of FMeC1 has been shown
to inhibit cognitive decline and reduce amyloid deposition in APP/
PS1 mice, which suggests a therapeutic potential of FMeC1 for
preventing AD [16]. FMeC1 has been shown to inhibit thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Structures of curcumin and its derivatives
Name Structure MW C log P IC50
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Table 1 (continued )
Name Structure MW C log P IC50
(mM)
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Name Structure MW C log P IC50
(mM)
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Name Structure MW C log P IC50
(mM)
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Name Structure MW C log P IC50
(mM)
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O
OH
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HO
O CF3F3C
516.39 6.70 N.D.
MW: Molecular weight. C log P: C log P values calculated in Chem Draw software. IC50: The half-maximal inhibitory concentrations with regard to ThT ﬂuorescence were used
to evaluate binding activities of the curcumin derivatives to Aβ aggregates, which were measured as described in Section 2.
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with Aβ during the aggregation state in vitro and to cause in-
creasingly lower molecular size Aβ aggregates and possibly reduce
cell toxicity [16]. In addition, FMeC1 binds not only to ﬁbrillar Aβ
aggregates but also to soluble oligomeric Aβ species [17]. Soluble
oligomers rather than monomeric or insoluble ﬁbrillar Aβ ag-
gregates are believed to have a major role in neuronal and synaptic
dysfunction in AD [18]. Therefore, it is possible that the interaction
of FMeC1 with soluble oligomers reduces toxicity by altering the
behavior of the oligomers.
To date, we have synthesized a series of novel curcumin deri-
vatives (called the Shiga-Y series) other than FMeC1 [19]. The
purpose of the present study was to identify candidates in our
collection that are effective in AD by investigating the inhibitory
effects of our curcumin derivatives on Aβ aggregation and the cell
toxicities of Aβ aggregates.2. Materials and methods
2.1. Materials
Curcumin was purchased from Wako (Osaka, Japan). Curcumin
derivatives were synthesized as described in Supplementary
methods Section. The structures of curcumin and the derivatives
are shown in Table 1. In the previous study, we termed SY5 and
SY6 as FMeC1 and FMeC2, respectively; however, here we use the
original names: SY5 and SY6.
2.2. Preparation of Αβ aggregates
Lyophilized Αβ (1–42) peptide (Peptide Institute, Osaka, Japan)
was dissolved in cold 1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP;
Wako) at 1 mM and incubated at 37 °C for 1 h. The HFIP acts as a
hydrogen-bond breaker and is used for eliminating pre-existing
structural inhomogeneities in Αβ [20]. An aliquot of the solution
containing the dissolved peptide was collected in microcentrifuge
tubes, and the HFIP was removed by evaporation. The resulting
peptide was stored as a ﬁlm at 30 °C. Immediately prior to use,
the HFIP-pretreated Αβ (1–42) was resuspended to a ﬁnal con-
centration of 5 mM in anhydrous dimethyl sulfoxide (DMSO)
(Sigma-Aldrich, St. Louis, MO, USA) by pipette mixing followed by
vortex mixing. To induce aggregation of Αβ, the 5 mM Αβ (1–42)
was diluted to 10 mM in phosphate-buffered saline (PBS), and the
solution was incubated for 24 h at 37 °C. To investigate the effects
of curcumin and its derivatives on Αβ aggregation, the com-
pounds, which were dissolved to a concentration of 1.5 mM inDMSO, were added to 10 mM Αβ (1–42) to obtain a ﬁnal con-
centration of 30 mM. After 24 h of incubation, Αβ was used for cell
viability assays and electrophoresis. The concentration of the
compounds (30 mM) used in the present study was determined on
the basis of the solubility of the compounds and our previous
study. Curcumin and the derivatives used in the present study
could be dissolved in the above solution at 30 mM, but some were
not soluble at 100 mM. In addition, our previous study showed
signiﬁcant inhibition of Aβ aggregation by 30 mM SY5, which in-
dicated that Z30 mM was high enough to show an inhibitory ef-
fect on Aβ aggregation. Therefore, the concentration of 30 mM was
selected in the present study. The experimental procedures used
such as those used during the incubation with Aβ and in the cell
viability assay were performed under dark conditions to protect
the compounds from light exposure because curcumin and the
derivatives were probably sensitive to light.
2.3. Native gel electrophoresis
Aβ (1–42) samples were diluted to 2.25 mM in native sample
buffer (BioRad, Hercules, CA), and 10 mL of each was loaded under
native conditions onto 5–20% precast polyacrylamide gels (Su-
perSep Ace; Wako), electrophoresed in native buffer at 100 V for
4 h at 4 °C, and transferred to PVDF membrane (Immobilon-P;
Merck Millipore, Billerica, MA) at 10 V for 1 h. The membrane was
subject to Western blotting as described below.
2.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and western blotting
Aβ samples were diluted 4 to 2.25 mM in sample buffer
(62.5 mM Tris, pH 6.8, 1% SDS, 25% glycerol) without heating.
Samples (10 mL) were separated on 10–20% precast polyacrylamide
gels (SuperSep Ace; Wako) and transferred to a polyvinylidene
diﬂuoride membrane at 10 V for 1 h. The membranes were
blocked with 5% skim milk in Tris-buffered saline (TBS; 25 mM
Tris–HCl, pH 7.4, 0.9% NaCl) containing 0.1% Tween 20 (TBS-T),
washed for 10 min with TBS-T, and incubated with mouse mono-
clonal anti-Aβ antibody (1:1000) (clone 6E10; Covance, Princeton,
NJ, USA) in TBS-T for 1 h at room temperature. After washing three
times for 10 min with TBS-T, the membrane was incubated with
horseradish peroxidase-conjugated anti-mouse IgG antibody
(1:20,000; Jackson ImmunoResearch, West Grove, PA, USA) in TBS-
T containing 0.5% skim milk for 1 h at room temperature. The
membranes were then washed three times for 10 min with TBS-T.
Immunoreactive proteins were visualized by chemiluminescence
(SuperSignal West Pico; Thermo Scientiﬁc, Rockford, IL, USA) using
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For semi-quantitative analysis, band intensities in the ranges of
15–20, 20–37, 37–75, and 75–200 kDa relative to the marker in-
tensities in SDS-PAGE were measured using image processing
software (Image J; National Institutes of Health, Bethesda, MD,
USA). The results were expressed as percentages relative to the
control condition intensities (Aβ aggregates with DMSO).
2.5. Cell culture
The human neuroblastoma cell line, SH-SY5Y (ATCC, Manassas,
VA, USA), was cultured in Dulbecco's modiﬁed Eagle's medium/
Ham's F-12 (1:1) with L-glutamine, sodium pyruvate, and N-2-
hydroxyethylpiperazine-N-2′-ethanesulfonic acid (referred to as
HEPES) (Nacalai Tesque, Kyoto, Japan) supplemented with 10%
(v/v) fetal bovine serum, 100 µ/mL penicillin, and 100 µg/mL
streptomycin, and kept at 37 °C in humidiﬁed 5% CO2/95% air.
2.6. Cell viability
To evaluate cell viability, we performed the 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
as an index of surviving cells, according to the instruction manual
(MTT Cell Count Kit; Nacalai Tesque). The SH-SY5Y cells were
seeded at 5104 cells/well in a 96-well microplate. Twenty-four
hours after plating, the culture medium was replaced with 100 mL
of fresh medium with or without Aβ and curcumin compounds.
After 24 h of incubation at 37 °C in a humidiﬁed atmosphere, 10 mL
of 5 mg/mL MTT solution was added to the wells, and the cells
were incubated for an additional 4 h at 37 °C in a humidiﬁed at-
mosphere. Then, 100 mL of solubilization solution (isopropanol/
0.04 mol/L HCl) was added to the well, and the plate was kept
overnight at 37 °C in a humidiﬁed atmosphere to completely dis-
solve the formazan. Optical density was then measured in tripli-
cate as technical replicates at 570 nm at a reference wavelength of
700 nm using a microplate reader (Inﬁnite M200; Tecan, Männe-
dorf, Switzerland). Optical density (OD)700 values were subtracted
from OD570 values to obtain corrected OD values, and the cell
viability was calculated using the following formula: Cell viability
(%)¼[(corrected OD of test samplecorrected OD of 100% death
control)/(corrected OD of untreated controlcorrected OD of 100%
death control)]100.
We tested cell viability with each of the following compounds
in multi-well assay plates: DMSO, curcumin, MR195, SY1, SY2, SY4,
SY5, SY6, SY7, SY8, SY9, SY10, SY11, SY12, SY13, SY14, SY15, SY16,
SY17, SY18, and SY20. Three wells per plate were assigned to each
compound, and optical density was measured in every well, then
averaged for each compound on the plate. This set of tests was run
three times (that is, in three identical plates) so that three in-
dependent three-well experiments were done for each compound,
and the optical density measurements were presented as
mean7standard error of the mean (SEM) for each compound. In
the same way, we tested cell viability with DMSO, SY21, SY22,
SY23, SY26, SY27, SY28, SY29, SY30, SY31, SY32, SY33, SY34, SY35,
SY36, SY37, SY38, SY39, SY40, SY41, SY42, and SY43 following the
same procedure. The DMSO was used for quality control in both
sets of measurements, and so it was tested 6 times, whereas each
compound was tested 3 times, at 3 wells per plate.
2.7. Thioﬂavin T ﬂuorescence assay
The half-maximal inhibitory concentrations (IC50) with regard
to Thioﬂavin T (ThT) ﬂuorescence were used to evaluate binding
activities to Aβ aggregates of the curcumin derivatives. ThT was
diluted to a concentration of 5 mM in 50 mM glycine–NaOH (pH
8.5), and the solution was stored at room temperature in the darkbefore use. To measure IC50 values, a broad concentration range
(12.5 nM–25 mM) using ﬁve concentration points of the curcumin
derivatives were each mixed with 2 mL of Aβ aggregates in a well
of a black 96-well non-binding plate (Greiner Bio-One, Frick-
enhausen, Germany). Then, 200 mL of 5 mM ThT solution was ad-
ded to each well. The ﬂuorescence of ThT was measured using a
FlexStation (Molecular Devices, Sunnyvale, CA, USA) at an excita-
tion wavelength of 440 nm, an emission wavelength of 490 nm,
and a cut off wavelength of 475 nm. The IC50 values were esti-
mated using GraphPad Prism (GraphPad Software, La Jolla, CA,
USA).
2.8. Statistical analysis
The results were presented as mean7standard error of the
mean (SEM) of at least three independent experiments. Statistical
signiﬁcance was determined by one-way analysis of variance
(ANOVA) followed by the Dunnett post hoc test for multiple
comparisons (GraphPad Prism 6; GraphPad Software).3. Results
3.1. Changes in the proﬁles of Aβ (1–42) aggregates formed in the
presence of curcumin derivatives
We investigated the solubility of curcumin and several deri-
vatives which we prepared including SY5, SY12, SY28, SY31, and
SY33. Thus, we prepared 1.5 mM curcumin and its derivatives in
100% DMSO as stock solutions. Then, the solutions were diluted
with 10 mM PBS (containing 2% DMSO) to make 30 mM ﬁnal con-
centrations. We obtained a clear yellowish-orange solution in each
case. Then, we further conﬁrmed absence of precipitation in two
ways. First, we looked for any precipitate from each solution by
light microscopy, as follows. Two microliters of the solution were
transferred to a glass slide, which was covered with a slip. When
we looked at the slides through a light microscope, we observed
no precipitation in any sample. However, when we made 200 mM
curcumin solution, we clearly observed precipitates from the so-
lution. Next, we looked for precipitates from the solutions after
centrifugation at 50,000 rpm (104,300g) for 60 min at 20 °C. No
precipitates were observed in the bottom of any samples.
We performed electrophoresis to evaluate the proﬁles of Aβ (1–
42) prepared by incubation with curcumin and the derivatives for
24 h at 37 °C. In native-PAGE analysis, Aβ (1–42) prepared by in-
cubating with DMSO for 24 h at 37 °C showed a band pre-
dominantly at the top of the gel, which indicated the formation of
Aβ aggregates (Fig. 1A). There were marked smear bands in Aβ (1–
42) prepared with the compounds for 24 h. The smear bands in-
dicated formation of lower molecular weight Aβ aggregates and
oligomers. The SDS-PAGE proﬁles showed an increase in mono-
mers, trimers, and tetramers as well as in the smear bands in Aβ
(1–42) prepared with the compounds for 24 h relative to those in
the Aβ (1–42) aggregates formed in the presence of vehicle control
(Fig. 1B). Comparison of the bands between native- and SDS-PAGE
showed that monomers, trimers, and tetramers that did not ap-
pear by native-PAGE were detected by SDS-PAGE, which suggested
that these Aβ species were generated by the disassembly of ag-
gregates derived from SDS processing during sample preparation.
In contrast, Aβ (1–42) products prepared with the compounds that
showed many smear bands in native-PAGE tended to give many
smear bands in SDS-PAGE, which suggested that the smear bands
of Aβ (1–42) in SDS-PAGE could be indicative of the formation of
lower molecular weight Aβ aggregates under native conditions.
In semi-quantitative analysis, SY5, SY12, SY15, SY26, SY28, and
SY33 showed signiﬁcant increases in the densities of the bands of
Fig. 1. Effect of selected curcumin derivatives on the aggregation of Aβ (1–42). Representative SDS-PAGE (A) and native-PAGE (B) proﬁles of Aβ (1–42) prepared by incubating
with DMSO as the vehicle control, curcumin (Cur), SY5, SY12, SY28, SY31, and SY33 for 24 h at 37°C. Marked smear bands were observed for SY5, SY12, SY28, SY31, and SY33
treated Aβ (1–42) in both SDS-PAGE (A) and native-PAGE (B). Gel images of Aβ prepared with DMSO, Cur, SY5, and SY12 were taken from one gel, and gel images of Aβ
prepared with SY28, SY31, and SY33 were taken from another gel. Arrowheads in (A) and (B) indicate the position of the top of the gel. (C) Cell viability was measured in SH-
SY5Y cells at 24 h after exposure to Aβ (1–42) prepared with DMSO as the vehicle control, curcumin (Cur), SY5, SY12, SY28, SY31, and SY33. Data are the means7SEMs of at
least three independent experiments. Signiﬁcance (Dunnet post-test after ANOVA): npo0.05, nnpo0.01 vs. DMSO. The values of cell viability in all compounds measured in
the present study are presented in Table 2. (D) Competition curves for Cur, SY5, SY12, SY28, SY31, and SY33 in the Thioﬂavin T (ThT) competition study. The half-maximal
inhibitory concentrations (IC50) with regard to ThT ﬂuorescence were used to evaluate binding activities of the curcumin derivatives to Aβ aggregates. The IC50 values in all
compounds measured in the present study are listed in Table 2. (E-H) Band intensities in the ranges of 15–20 (E), 20–37 (F), 37–75 (G), and 75–200 kDa (H) were measured
by SDS-PAGE for semi-quantitative analysis of Aβ (1–42) prepared by incubating with DMSO as the vehicle control, curcumin (Cur), SY5, SY12, SY28, SY31, and SY33. Data are
the means7SEMs of at least three independent experiments. Signiﬁcance (Dunnet post-test after ANOVA): npo0.05, nnpo0.01, nnnpo0.001, vs. DMSO. The values of the
band intensities for all compounds measured in the present study are listed in Table 2.
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relative to those of Aβ (1–42) prepared with vehicle control
(DMSO) (Table 2). SY14, SY31, and SY34 showed signiﬁcant in-
creases in the densities in the ranges of 37–75 and 75–200 kDa
(Table 2). In addition, there were signiﬁcant increases in the
densities only in the ranges of 15–20 kDa for SY2, 20–37 kDa for
SY37 and SY38, and 75–200 kDa for SY43 (Table 2). Taken together,
14 of 41 compounds showed a signiﬁcant increase in the densities
of the bands of Aβ (1–42) by incubation during the aggregation
process relative to those of Aβ (1–42) prepared in the presence of
the vehicle control.
3.2. Effect of curcumin derivatives on cell toxicity of Aβ aggregates
We investigated the cell toxicity of Aβ (1–42) incubated with cur-
cumin and its derivatives during the aggregation process. To evaluate
cell viability, Aβ (1–42) prepared by incubating at a concentration of
10 mM for 24 h at 37 °C in the presence of 30 mM curcumin derivatives
was treated in SH-SY5Y cells for 24 h at ﬁnal concentrations of 0.3 mM
Aβ (1–42) and 0.9 mM curcumin derivatives. Signiﬁcantly higher cell
viability was observed following exposure to Aβ (1–42) incubated
with SY12, SY28, SY31, SY32, and SY33 during the aggregation process,
than following exposure to Aβ (1–42) incubated with vehicle control
(po0.05 for SY12, SY28, SY32, and SY33; po0.01 for SY31) (Viability A
in Table 1). We next investigated the effect of simultaneous treatment
with 0.9 mM curcumin derivatives and 0.3 mM Aβ (1–42) aggregates.
Simultaneous treatment did not improve cell viability 24 h afterexposure to Aβ (1–42) aggregates, but there was signiﬁcant reduction
in cell viability by simultaneous treatment with SY4 relative to that by
treatment with the vehicle control (po0.05; Viability B in Table 1). We
further evaluated cell viability 24 h after treatment with 0.9 mM cur-
cumin derivatives alone. There was no signiﬁcant difference in cell
viability after treatment with curcumin derivatives alone except for
SY14 and SY18; these two compounds signiﬁcantly reduced cell via-
bility (po0.05 for SY14; po0.001 for SY18) (Viability C in Table 2).3.3. Correlation of cell viability and increased density in SDS-PAGE
We investigated whether there were correlations between cell
viabilities after exposure to Aβ (1–42) incubated with the com-
pounds for 24 h, and the densities of the SDS-PAGE bands of Aβ
(1–42) incubated with the compounds. Signiﬁcant positive corre-
lations were observed between the cell viabilities and densities in
all ranges of 15–20 (Fig. 2A; Pearson's r¼0.461; po0.001), 20–37
(Fig. 2B; Pearson's r¼0.535; po0.001), 37–75 (Fig. 2C; Pearson's
r¼0.478; po0.01), and 75–200 kDa (Fig. 2D; Pearson's r¼0.427;
po0.01) (Fig. 2). Signiﬁcant positive correlations were also ob-
served between the cell viabilities and ClogP values of the curcu-
min derivatives (Pearson's r¼0.474; po0.01) (Fig. 2). In contrast,
there were no correlations between the molecular weights of the
curcumin derivatives and cell viabilities (Pearson's r¼0.069;
p¼0.666) or between the IC50 values and cell viabilities (Pearson's
r¼0.096; p¼0.612) (data not shown).
Table 2
Comparison of densities determined by SDS-PAGE and of cell viabilities
Name Density Viability
n 15–20 kDa (%) 20–37 kDa (%) 37–75 kDa (%) 75–200 kDa (%) A. Exposure to Aβ pre-in-
cubated with the
compounds
B. Simultaneous treatment with
Aβ aggregates and the
compounds
C. Compound alone
n % n % n %
DMSO 14 100723 100741 100727 100723 6 56.171.1 6 54.070.9 6 102.773.5
Cur 14 253750 10127103 472749 414764 3 61.671.7 3 53.571.5 3 97.577.3
MR195 5 3437161 14117539 6187183 4377100 3 60.972.1 3 56.572.3 3 97.176.7
SY1 3 5347410 13507641 6067154 463787 3 58.871.9 3 51.271.7 3 103.372.2
SY2 3 11897634*** 24547817 10247264 9657214 3 58.571.4 3 50.473.6 3 101.472.0
SY4 3 281786 6367135 389737 217731 3 52.970.7 3 45.672.6* 3 91.673.2
SY5 14 5987170* 25217588*** 10477212** 9817209** 3 62.771.3 3 54.671.5 3 102.273.6
SY6 3 103725 2257118 220761 200752 3 57.771.6 3 55.173.0 3 99.472.2
SY7 5 301778 14447429 564794 473771 3 59.771.8 3 55.373.0 3 102.572.0
SY8 3 179736 14257211 9137119 825765 3 59.371.7 3 48.272.1 3 91.873.7
SY9 3 54722 74755 125723 9774 3 53.271.2 3 50.773.2 3 94.272.5
SY10 3 2477141 14167454 6667177 5757125 3 60.572.4 3 52.172.2 3 92.971.7
SY11 3 3317138 18397607 9057331 8057253 3 60.872.3 3 52.972.5 3 98.272.0
SY12 3 10407220** 676871205*** 21627263*** 15797178** 3 64.072.8* 3 51.972.3 3 91.672.3
SY13 5 5367170 24077610 12037280* 10307185* 3 63.672.2 3 57.571.6 3 96.272.9
SY14 3 7687307 439371906*** 212671014*** 17507927 *** 3 59.872.0 3 50.672.0 3 84.571.7*
SY15 3 9917405* 510971379*** 20797609*** 20027450*** 3 60.172.2 3 52.172.4 3 90.970.8
SY16 3 85711 5347134 216764 161730 3 57.972.3 3 51.371.6 3 94.172.8
SY17 3 3047173 7867316 4797189 5247277 3 62.272.6 3 53.272.1 3 94.172.2
SY18 3 98730 239766 183712 155712 3 58.572.3 3 49.673.1 3 69.577.7***
SY20 3 203793 9847292 5867191 5487126 3 62.472.3 3 54.871.5 3 89.0712.7
SY21 5 144728 3637104 341771 342773 3 58.872.0 3 50.570.4 3 96.771.7
SY22 3 234790 6267365 437796 457786 3 59.372.6 3 50.570.7 3 95.873.6
SY23 3 3807141 13117489 6077234 5017204 3 58.272.3 3 52.671.1 3 97.972.4
SY26 3 11957489*** 562271637*** 21707488*** 24427376*** 3 60.171.4 3 54.370.9 3 97.671.6
SY27 3 299787 11207156 6397177 556758 3 60.871.8 3 53.370.2 3 98.575.3
SY28 3 12017129*** 100827326*** 59337438*** 73267908*** 3 64.870.4* 3 54.670.9 3 95.973.1
SY29 3 3237127 10817223 520785 6527112 3 58.071.7 3 52.671.5 3 99.676.2
SY30 3 2487156 12617700 6327282 5707231 3 62.271.8 3 53.771.8 3 98.673.1
SY31 3 8577447 39117635** 19767151*** 18617227*** 3 66.872.0** 3 55.371.2 3 94.274.1
SY32 3 2847179 12817648 6867292 6147174 3 64.772.1* 3 54.172.4 3 98.273.6
SY33 3 11997584*** 684973510*** 297671352*** 260671036*** 3 65.171.8* 3 53.870.8 3 97.874.2
SY34 3 877784 63867900*** 38167705*** 30587854*** 3 59.172.4 3 53.971.4 3 94.173.4
SY35 3 185732 281754 289736 294725 3 50.971.5 3 51.671.7 3 93.772.9
SY36 3 122747 117778 211735 304753 3 55.271.1 3 51.171.3 3 96.175.4
SY37 3 6897171 39457784** 14737377 14307285 3 60.371.5 3 53.071.5 3 93.074.1
SY38 3 4907122 31877853* 12957384 10327313 3 62.972.1 3 51.171.6 3 91.673.9
SY39 3 2707128 3487127 265744 398737 3 50.671.5 3 51.871.2 3 94.776.7
SY40 3 231772 2447110 275763 345775 3 53.671.6 3 52.270.9 3 95.276.0
SY41 3 301784 15847115 7287164 9497147 3 61.971.7 3 55.970.4 3 93.475.9
SY42 3 132717 4277209 2637104 313798 3 60.871.8 3 53.670.8 3 88.676.3
SY43 3 3577103 14577119 9457135 15857488** 3 57.672.0 3 56.070.9 3 89.775.0
Density: Aβ samples prepared by incubating with curcumin and the derivatives for 24 h at 37 °C were subjected to SDS-PAGE followed by Western blotting. The densities of
the bands in the ranges of 15–20, 20–37, 37–75, and 75–100 kDa were then measured by using Image J. Viability (A): Cell viabilities after exposure to Aβ incubated with the
compounds for 24 h at 37 °C; Viability (B): Cell viabilities after simultaneous treatment with Aβ aggregates and the compounds; and Viability (C): Cell viabilities after
treatment with the compounds alone. The results are presented as means7SEMs of at least three independent experiments. Statistical signiﬁcance was determined by one-
way analysis of variance followed by the Dunnett post hoc test for multiple comparisons.
Signiﬁcance (Dunnet post-test after ANOVA): npo0.05, nnpo0.01. nnnpo0.001 vs. DMSO.
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In this study, we investigated the effects of our curcumin de-
rivatives on Aβ aggregation and its cell toxicity. According to the
SDS-PAGE proﬁles, 14 of 41 compounds showed signiﬁcant in-
creases in the densities of the bands of Aβ (1–42) by incubation
during the aggregation process relative to those of Aβ (1–42)
prepared in the presence of the vehicle control. Among the com-
pounds, SY12, SY28, SY31, and SY33 also reduced the cell toxicities
of the Aβ aggregates by incubation during the aggregation process.
Taking these ﬁndings together, we propose SY12, SY28, SY31, and
SY33 as therapeutic candidates for preventing AD.
Several reports have shown the potential of curcumin derivatives
for modulating Aβ metabolism [21–24], antioxidative stress, and
cancer prevention [25,26]. Reinke and Gestwicki outlined the optimallinker length and ﬂexibility (or rigidity) of two phenyl groups of
curcumin, for inhibition of Aβ aggregation [24]. In addition, they
proposed that hydroxy substitutions on the aromatic end groups are
required for inhibition [24]. In the present study, our candidate
compounds ﬁt the model proposed by Reinke and Gestwicki [24].
Furthermore, the effect of a curcumin derivative with a 1,7-bis (4′-
hydroxy-3′-triﬂuoromethoxyphenyl) group (SY5) was stronger than
that of a curcumin derivative with a 1,7-bis (4′-hydroxy-3′-methox-
yphenyl) group (SY23), which suggested that triﬂuoromethoxy groups
on aromatic rings are favorable groups for inhibiting Aβ aggregation.
In addition, curcumin derivatives that showed effects on Aβ ag-
gregation had at least one hydroxy group on the aromatic groups in
their structure. In contrast, curcumin derivatives without hydroxy
groups on the aromatic groups (SY7, SY8, SY9, SY18, SY21, SY22, SY42)
showed no effects on Aβ aggregation. Although, curcumin derivatives
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Fig. 2. Positive correlations between the cell viabilities and densities of Aβ in SDS-PAGE or ClogP values. (A-D) Signiﬁcant positive correlations were observed between the
cell viabilities after exposure to Aβ (1–42) prepared with the compounds and the densities of the bands of Aβ (1–42) in the ranges of 15–20 (A; Pearson’s r¼0.461; po0.001),
20–37 (B; Pearson’s r¼0.535; po0.001), 37–75 (C; Pearson’s r¼0.478; po0.01), and 75–200 kDa (D; Pearson’s r¼0.427; po0.01). (E) Positive correlations between cell
viabilities and ClogP values (Pearson’s r¼0.474; po0.01) were observed. Curcumin, SY5, and selected compounds (SY12, SY28, SY31, and SY33) are indicated by open circles,
gray circles and red circles, respectively.
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to exert higher inhibitory effects on Aβ oligomerization than curcu-
min [23], according to our results and the above model proposed by
Reinke and Gestwicki, we assumed that the hydroxy groups on the
aromatic groups in curcumin derivatives are essential for inhibiting
Aβ aggregation. Furthermore, the curcumin derivatives that we pro-
pose here, SY12, SY28, SY31, and SY33, have substituents at the C-4
position. Taken together, we assumed that the combination of 1,7-bis
(4′-hydroxy-3′-triﬂuoromethoxyphenyl) groups and a suitable sub-
stituent at the C-4 position were key inﬂuences on the therapeutic
effect of curcumin derivatives.
We previously reported signiﬁcant improvement of cell viabi-
lity by incubation of SY5 (FMeC1) with Aβ (1–42) aggregates
during the aggregation process [16]. In the present study, we ob-
served a marked increase in cell viability following incubation of
SY5 (FMeC1; Viability A in Table 1), as in the previous study.
However, we could not detect statistically signiﬁcant differences in
any improvements in cell viability, presumably because of the
lower power of the statistical analysis that we used. The power of
the test is reduced when the number of groups compared is in-
creased. Thus, even if a large increase in cell viability was observed
after the treatment, it was difﬁcult to assign statistical signiﬁcance
when we compared 42 compounds at once.
Previous studies have demonstrated that curcumin can bind to
β-sheeted structures in Aβ ﬁbrils and inhibit further elongation of
the ﬁbrillar structures [11,12]. Furthermore, Yang et al. [12] also
showed inhibition of Aβ oligomer formation by curcumin. There-
fore curcumin and its derivatives may inhibit both Aβ oligomer-
ization and ﬁbrillogenesis. However, it was difﬁcult to know the
exact sizes of the Aβ aggregates and oligomers that we prepared in
the present study; thus, we could not investigate the mechanisms
of inhibition of Aβ oligomerization.In the SDS-PAGE analysis, we measured the densities of the
bands. Interestingly, SY2 treatment induced signiﬁcant increases
in the densities of the band corresponding to trimers and tetra-
mers of 15–20 kDa, but not in the other band ranges. However, Aβ
aggregates that were formed with SY2 did not enhance the toxicity
of the Aβ aggregates. In addition, native-PAGE analysis showed
almost no bands corresponding to trimers and tetramers of 15–
20 kDa. These ﬁndings suggest that the bands of trimers and tet-
ramers in SDS-PAGE might not reﬂect the appearance of these
species in real samples; therefore, these compounds may not be
responsible for increasing cell toxicity.
It is difﬁcult to dissolve curcumin in an aqueous solution because of
poor solubility. In the present study, we prepared 1.5 mM curcumin
and our derivatives in DMSO as stock solutions. Then, the solutions
were diluted in 10 mM in PBS (with 2% DMSO) at a ﬁnal concentration
of 30 mM. Thus, 4% DMSO was present in the ﬁnal reaction mixtures
and would have contributed to dissolving the compounds in the so-
lutions. In addition, several studies have reported using 430 mM
curcumin in aqueous solutions [11,12,24]. Thus, we thought that the
use of curcumin at 30 mM was reasonable to investigate its effects.
There were signiﬁcant positive correlations between the cell vi-
abilities and densities in the ranges of 15–20, 20–37, 37–75, and 75–
200 kDa in the SDS-PAGE proﬁles after exposure to Aβ aggregates
incubated with curcumin derivatives. Thus, it is likely that curcumin
derivatives with higher inhibitory effects on Aβ aggregation con-
tribute to increasing cell viability, which suggests that Aβ species
were formed in our experiments with compounds that had weaker
cell toxicity. In addition, our results indicated that the C log P values of
the curcumin derivatives were also involved in the effects via un-
known mechanisms. Further study is needed to elucidate the me-
chanisms underlying the effects of the curcumin derivatives.
It has been reported that curcumin is apparently a highly
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[5]. Curcumin binds to proteins such as P-glycoprotein, multidrug-re-
sistance proteins 1 and 2, glutathione, protein kinase C, ATPase, ErbB2,
and alpha1-acid glycoprotein and inhibits the activation of various
transcription factors and expression of growth- and metastasis-pro-
moting genes and also downregulates the activity of multiple kinases.
The dicarbonyl unit is one of the causative moieties of curcumin be-
cause molecules containing a β-diketone are known to form stable
complexes with multivalent metal cations [27]. For example, curcumin
forms chelates with metals such as boron, copper, aluminum, mag-
nesium, zinc, lead, cadmium, and ferrous (Fe2þ) and ferric (Fe3þ) iron
as well as with metal oxides such as vanadyl and nonmetals such as
selenium. These interactions are often beneﬁcial for anti-inﬂammatory
effects, anti-tumor effects, and anti-AD effects. On the other hand, the
interactions of curcumin with essential molecules for life could cause
off-target toxicity, as shown by three compounds (SY4, SY14, SY18) in
the present study. Although we did not investigate the off-target
toxicity induced by the curcumin derivatives in detail in this study, it
would be very useful to understand the mechanisms of the off-target
toxicity to develop curcumin derivatives as therapeutic drugs for AD.
There were potential weaknesses in the present study. First, only
an in vitro study was conducted to probe the effect of the compounds.
Senile plaques consist of not only Aβ aggregates but also of various
proteins and metals. Therefore, the Aβ aggregates used in this study
might have been highly artiﬁcial. Second, more detailed investigations
regarding the inhibition of Aβ oligomer formation is required to
elucidate the mechanisms of the effects of the compounds. Finally,
there was little evidence of structure–function relationships of the
compounds. As a future research direction, an in vivo study using an
animal model of AD and including experiments focused on inhibition
of Aβ oligomer formation by the compounds should be conducted
with candidates selected on the basis of the results of the present
study. An additional goal would be to elucidate the structure–function
relationships of the compounds.5. Conclusions
We propose SY12, SY28, SY31, and SY33 as curcumin derivatives
that may prevent AD. These curcumin derivatives exhibited high
inhibitory effects on Aβ aggregation and induced formation of
lower molecular size Aβ species with weaker cell toxicities. We
expect that these compounds will exert therapeutic effects that
prevent AD in future in vivo studies.Conﬂict of interest
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